Navigation Links
Dendreon Announces $47 Million Registered Direct Offering
Date:4/3/2008

SEATTLE, April 3, 2008 /PRNewswire-FirstCall/ -- Dendreon Corporation (Nasdaq: DNDN) today announced that it has entered into a definitive agreement with an institutional investor to sell 8.0 million shares of its common stock and warrants to purchase up to 8.0 million shares of its common stock for gross proceeds of approximately $47 million, before deducting placement agent fees and estimated offering expenses, in a "registered direct" offering. The investor has agreed to purchase the shares of common stock and warrants to purchase common stock at a negotiated purchase price of $5.92 per share and a warrant exercise price of $20.00 per share. For the common stock purchased, this represents a 17% premium to the closing bid price of the common stock on April 2, 2008. The warrants will be exercisable at any time on or after October 8, 2008 and prior to the seventh anniversary of the closing of the transaction. The closing bid price of the common stock on the Nasdaq Global Market on April 2, 2008 was $5.06 per share. Lazard Capital Markets LLC served as sole placement agent for the offering.

The securities described above are being offered by Dendreon pursuant to registration statements previously filed and declared effective by the Securities and Exchange Commission (the "SEC"). The transaction is expected to close on or about April 8, 2008, subject to customary closing conditions. We intend to use the net proceeds from the sale of the shares to fund our commercialization activities for Provenge(R) (sipuleucel-T), including the investment in specialized technology systems; to fund clinical trials for PROVENGE and our other product candidates; to fund our other research and preclinical development activities for our active immunother
'/>"/>

SOURCE Dendreon Corporation
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3

Related biology technology :

1. Dendreon Reports Fourth Quarter and 2007 Year End Financial Results
2. FDA Agrees to Amend Dendreons Special Protocol Assessment for Phase 3 IMPACT Study of PROVENGE
3. -Dendreon to Hold Conference Call on Thursday, March 13, 2008 at 11:00 AM ET-
4. Dendreon Publishes Manuscript on CD54 as a Surrogate Marker of Antigen Presenting Cell Activation
5. Dendreon Announces Webcast Presentation at BIO CEO & Investor Conference
6. Dendreon Promotes Dr. Mark Frohlich to Senior Vice President of Clinical Affairs and Chief Medical Officer
7. Dendreon Reports Third Quarter 2007 Financial Results
8. Dendreon Announces Webcast Presentations at Upcoming Investor Conferences
9. Dendreon Secures $130 Million Committed Equity Financing Facility
10. Dendreon Announces Webcast Presentation at UBS Life Sciences Conference
11. Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/10/2014)... Toronto, Canada (PRWEB) July 10, 2014 ... often present in very low abundance and are ... quite challenging and time-consuming. , Join presenters Dr. ... Laboratories, and Dr. John Anders, Head of Quality ... mass spectrometer-based approach that can speed detection and ...
(Date:7/10/2014)... July 10, 2014 Terascala, the industry ... that Alan Swahn, a former vice president of product ... as vice president of marketing. Terascala’s software when combined ... NetApp create the highest performance and most reliable solutions ... to guide Terascala’s channel expansion and broaden its product ...
(Date:7/10/2014)... Angeles, CA (PRWEB) July 10, 2014 ... and Bioanalytical techniques during 18-20 August, 2014 at Double ... critically review the recent developments in Analytical & Bioanalytical ... the globe. , Speaking on this occasion, Dr. Srinubabu ... Analytica Acta conference is a remarkable one in ...
(Date:7/10/2014)... Ind. , July 10, 2014 /PRNewswire/ ... its use of capnography for respiratory monitoring ... group of healthcare leaders in embracing state-of-the-art ... how effectively patients are breathing and can ... occurs. By measuring the amount of carbon ...
Breaking Biology Technology:Novel Ms Techniques Speed Detection of Biopharmaceutical Product and Process Impurities, New Webinar Hosted by Xtalks 2Terascala Expands Executive Team 2Terascala Expands Executive Team 3A Critical Review of Analytical Techniques for Improved Living Standards 2A Critical Review of Analytical Techniques for Improved Living Standards 3A Critical Review of Analytical Techniques for Improved Living Standards 4Franciscan St. Anthony Health-Crown Point Underscores Patient Safety Commitment Through Expanded Use of Capnography 2
... Surveillance System Detects ... Emerging Pattern, ... hours,on a recent Friday, 20 people arrived, one by one, for ... various,gastrointestinal symptoms, including nausea and diarrhea., A coincidence? Or the ...
... CHAPEL HILL, N.C., May 22 Pharmaceutical and biotech,companies ... Assurance (QA) functions. This benchmarking study will help R&D,Quality ... Optimizing limited QA staff resources so that they have ... Optimizing services in regards to the FDA,s Risk-Bases method ...
... investor ... conference call, ... of BioElectronics Corporation (Pink Sheets: BIEL), the,developer of ActiPatch, an ... delivers pulsed,electromagnetic therapy, today issued the following summary of its ...
Cached Biology Technology:E. coli Outbreak in New Jersey? 2E. coli Outbreak in New Jersey? 3Best Practices in Quality Assurance and Risk-Based Approach for the Biopharmaceutical Industry 2BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 2BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 3BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 4BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 5BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 6BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 7BioElectronics Corporation - Substantial International Expansion Producing Sustained Revenue Growth-Company Reaches Monthly Break Even 8
(Date:7/11/2014)... Recent evidence has demonstrated that transplantation of mesenchymal stem ... rat or mouse models of Alzheimer,s disease (AD) and ... cerebral ischemia. Few studies are reported on the therapeutic ... with AD and on the effect on oxidative injury ... Yufang Yan and her team, School of Life Sciences, ...
(Date:7/11/2014)... Research and Markets has announced ... - Industry Analysis Size Share Growth Trends and Forecast ... http://photos.prnewswire.com/prnh/20130307/600769 The rising ... need for high level security in both private and ... as username and passwords, tokens etc. are vulnerable to ...
(Date:7/10/2014)... June 27, 2014  The American Academy of ... of Standards and Technology (NIST) and the Department ... research and forensic science expert members to the ... an element of the NIST,s Organization of Scientific ... the first appointments made to the new FSSB ...
Breaking Biology News(10 mins):International Biometrics Technology Market - Industry Analysis Size Share Growth Trends and Forecast to 2019 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 2Ten Members of the American Academy of Forensic Sciences Appointed to Forensic Science Standards Board (FSSB) 3
... (Sept. 27, 2010) -- Renowned international experts and ... vaccines for human papillomavirus and tuberculosis to a ... FIP Pharmaceutical Sciences World Congress (PSWC) in association ... Annual Meeting and Exposition in New Orleans, La., ...
... of African-American women in the US, the association between the ... type 2 diabetes mellitus (late onset diabetes) was studied for ... with diabetes, but the regular moderate intake of both caffeinated ... late onset diabetes significantly. This paper is ...
... Although the magnificent frigatebird may be the least likely ... the area, it turns out the Galapagos population of ... species warranting a new conservation status, according to a ... the Smithsonian,s National Museum of Natural History and the ...
Cached Biology News:Smithsonian researchers find differences between Galapagos and mainland frigatebirds 2